Wegeners Granulomatosis

Pathophysiology: Wegener's granulomatosis is a systemic autoimmune disease characterized by granulomatous vasculitis of the upper and lower respiratory tracts, glomerulonephritis and small vessel vasculitis. 90% of patients have pulmonary involvement. As the affected vessels are occluded, stroke developed with subsequent radiographic manifestations of ill-defined multiple bilateral opacities and delimit as myocardial is organized.

Treatment 
Corticosteroids: Medications such as prednisone help suppress the immune system and treat the early signs and symptoms of Wegener's granulomatosis. 
Immune suppressant medications: Most people require another immunosuppressive drug, such as cyclophosphamide, azathioprine or methotrexate, to counteract the body's immune reaction.

Research: Department of Endocrinology, Hospital Gene Pituitary participation has been described in 24 patients in the literature to date. A case of pituitary involvement in WG, and to present a literature review on this association. ral de Agudos Dr. Profesor J. M. Ramos Mejía conducted a research on Wegener's granulomatosis. They present a female patient with WG who evolved with central diabetes insipidus (CDI), panhypopituitarism, and mild hyperprolactinemia. MRI showed an infiltrative pattern.

Statistics: The mainstay of treatment for granulomatosis with polyangiitis (GPA) is a combination of corticosteroids and cytotoxic agents. Treatment should be tailored to appropriately treat GPA manifestations while minimizing long-term toxicities to the patient. Untreated generalized or severe GPA typically carries a dismal prognosis, with up to 90% of patients dying within 2 years, usually of respiratory or renal failure. Even non-renal GPA carries a mortality rate of up to 40%.